Netherlands AI system surpasses doctors in mesothelioma evaluation
Tap title to read story
Researchers at the Netherlands Cancer Institute have developed an artificial intelligence model that more accurately assesses pleural mesothelioma treatment response than human physicians and the current international RECIST criteria. Trained on more than 11,000 CT scans from 2,000 patients across 121 hospitals, the model analyzes complex imaging features to guide decisions on continuing, modifying, or stopping therapy. The peer-reviewed findings, published in The Lancet Oncology on June 18, 2026, represent the first global demonstration of AI outperforming specialists in this niche. Clinicians are beginning to integrate the tool into diagnostic workflows, with researchers stressing it is intended to support, not replace, medical judgment.
More context
Timeline
- 2018 Researchers begin assembling multi-hospital CT dataset
- 2020 Initial AI model architecture designed and tested
- 2022 Expanded training includes 11,000 CT scans
- Early 2025 Model benchmarked against RECIST criteria
- Late 2025 Multicenter validation confirms superior accuracy
- June 18, 2026 Study published in The Lancet Oncology
- June 2026 Clinicians start integrating model into workflows
- Today Researchers emphasize AI supports clinical judgment
Why it matters
This AI tool could mean more accurate treatment for mesothelioma, a rare cancer often linked to asbestos exposure. If you or a loved one are dealing with this disease, it could guide doctors to make better decisions about therapy.
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
